C54 - Multiple Sclerosis Therapy: Disease-modifying Treatment II

Event Time: Sunday April 23, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s): Bruce Cree MD, PhD, MCR, FAAN
Description: Disease-modifying treatments in MS are one of the most rapidly evolving areas of therapeutic intervention in neurology. As new treatments become available, the options for patients, and their prescribing physicians, increases. Many of the newer therapies have complex risk: benefit profiles and require specialized expertise for safe and effective administration. Faculty will focus on therapeutic strategies and risk mitigation of currently available disease-modifying therapies, discuss proper use of these drugs and risk assessment, and use specific examples to cover the most frequent issues arising from MS treatment strategies. This program complements C36: Multiple Sclerosis Therapy: Disease-modifying Treatment I and C116: Multiple Sclerosis Therapy: Symptom Management, but covers independent topics.
Completion Message: Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Ready to register for the 2018 AAN Annual Meeting?

Register Now

Related Courses